Cyclization in opioid peptides

Current Drug Targets

Volumn 14, Issue 7, 2013, Pages 798-816

  Piekielna, Justyna ^a   Perlikowska, Renata ^a   Gach, Katarzyna ^a   Janecka, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amide bonds; Analgesic activity; Carbonyl and guanidine bridges; Disulfide bonds; Monosulfide bonds; Opioid receptor affinity

Indexed keywords

NARCOTIC ANALGESIC AGENT; OPIATE PEPTIDE;

ANIMAL; BRAIN; CHEMISTRY; COMPARATIVE STUDY; CYCLIZATION; HALF LIFE TIME; HUMAN; METABOLISM; PAIN; REVIEW; SYNTHESIS; TISSUE DISTRIBUTION;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CYCLIZATION; HALF-LIFE; HUMANS; OPIOID PEPTIDES; PAIN; TISSUE DISTRIBUTION;

EID: 84891606822     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314070008     Document Type: Review

References (128)

1. Pleuvry BJ. Update on opioids. Curr Anaesth Crit Care 2003; 14: 155-9.
2. Olson GA, Olson RD, Vaccarino, et al. Endogenous opiates 1997. Peptides 1998; 19: 1791-843.
3. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993; 16: 506-10.
4. Feng Y, He X, Yang Y, et al. Current research on opioid receptor function. Curr Drug Targets 2012; 13: 230-46.
5. Georgoussi Z, Georganta EM, Milligan G. The other side of opioid receptor signalling: regulation by protein-protein interaction. Curr Drug Targets 2012; 13: 80-102.
6. Desroches J, Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets 2010; 11: 462-73
7. Mollereau C, Parmentier M, Mailleux P et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341(1): 33-8.
8. Rossi GC, Leventhal L, Pan YX, et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6- beta-glucuronide antinociception. J Pharmacol Exp Ther 1997; 281: 109-14.
9. Sánchez-Blázquez P, García-Espãna A, Garzón J. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther 1997; 280: 1423-31.
10. Joshi SK, Su X, Porreca F, et al. kappa -Opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action. J Neurosci 2000; 20: 5874-9.
11. Janecka A, Fichna J, Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004; 4: 1-18.
12. Gentilucci l. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr Topics Med Chem 2004; 4: 19-38.
13. Meunier JC, Mollereau C, Toll L et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-5.
14. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995 Nov 3; 270(5237): 792-4.
15. Wilson AM, Soignier RD, Zadina JE, et al. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 2000; 20: 1871-4.
16. Czapla MA, Gozal D, Alea OA, et al. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respir Crit Care Med 2000; 162: 994-9.
17. Hau VS, Huber JD, Campos CR, et al. Effect of guanidino modification and proline substitution on the in vitro stability and bloodbrain barrier permeability of endomorphin II. J Pharm Sci 2002; 91: 2140-9.
18. Tomboly C, Peter A, Toth G. In vitro quantitative study of the degradation of endomorphins. Peptides 2002; 23: 1573-80.
19. Han TS, Teichert RW, Olivera BM, et al. Conus venoms - a rich source of peptide based therapeutics. Curr Pharm Des 2008; 14: 2462-79.
20. Mouhat S, Andreotti N, Jouirou B, et al. Animal toxins acting on voltage-gated potassium channels. Curr Pharm Des 2008; 14: 2503-18.
21. Craik DJ, Mylne JS, Daly NL. Cyclotides: macrocyclic peptides with applications in drug design and agriculture. Cell Mol Life Sci 2010; 67: 9-16.
22. Katsara M, Tselios T, Deraos S, et al. Round and round we go: cyclic peptides in disease. Curr Med Chem 2006; 13: 2221-32.
23. DiMaio J, Schiller PW. A cyclic enkephalin analog with high in vitro opiate activity. Proc Natl Acad Sci USA 1980; 77: 7162-6
24. Di Maio J, Nguyen TM, Lemieux C, et al. Synthesis and pharmacological characterization in vitro of cyclic enkephalin analogues: effect of conformational constraints on opiate receptor selectivity. J Med Chem 1982; 25: 1432-8.
25. Mierke DF, Said-Nejad OE, Schiller PW, et al. Enkephalin analogues containing beta- naphthylalanine at the fourth position. Biopolymers 1990; 29: 179-96.
26. Rüthrich HL, Grecksch G, Schmidt R, et al. Linear and cyclic betacasomorphin analogues with high analgesic activity. Peptides 1992; 13: 483-5.
27. Schmidt R, Vogel D, Mrestani-Klaus C, et al. Cyclic betacasomorphin analogues with mixed mu agonist/delta antagonist properties: synthesis, pharmacological characterization, and conformational aspects. J Med Chem 1994; 37: 1136-44.
28. Vogel D, Schmidt R, Hartung K, et al. Cyclic morphiceptin analogs: cyclization studies and opioid activities in vitro. Int J Peptide Protein Res 1996; 48: 495-502.
29. Mollica A, Pinnen F, Stefanucci A, et al. The cis-4-amino-Lproline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues. J Med Chem 2012; 55: 3027-35
30. Mollica A, Pinnen F, Stefanucci A, et al. The cis-4-amino-Lproline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues: part 2. J Med Chem 2012; 55: 8477-82.
31. Schiller PW, Nguyen TM. Activity profiles of novel side-chain to side-chain cyclized opioid peptide analogs. Neuropeptides 1984; 5: 165-8.
32. Schiller PW, Nguyen TM, Lemieux C, et al. A novel side-chainlinked antiparallel cyclic dimer of enkephalin. FEBS Lett 1985; 191: 231-4.
33. Schiller PW, Nguyen TM, Lemieux C, et al. Synthesis and activity profiles of novel cyclic opioid peptide monomers and dimers. J Med Chem 1985; 28: 1766-71.
34. Schiller PW, Nguyen TM, Maziak LA, et al. Structure-activity relationships of cyclic opioid peptide analogues containing a phenylalanine residue in the 3-position. J Med Chem 1987; 30: 2094-9.
35. Vogel D, Schmidt R, Hartung K, et al. Cyclic morphiceptin analogs: cyclization studies and opioid activities in vitro. Int J Peptide Protein Res 1996; 48: 495-502.
36. Wilkes BC, Schiller PW. Conformation-activity relationships of cyclic dermorphin analogues. Biopolymers 1990; 29: 89-95.
37. Wilkes BC, Schiller PW. Comparative conformational analysis of [D-Pen2,D-Pen5]enkephalin (DPDPE): a molecular mechanics study. J Comput Aided Mol Des 1991; 5: 293-302.
38. Schiller PW, Weltrowska G, Dung NTM, et al. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem 1991; 34: 3125-32.
39. Richman SJ, Goodman M, Nguyen TM, et al. Synthesis and biological activity of linear and cyclic enkephalins modified at the Gly3-Phe4 amide bond. Int J Peptide Protein Res 1985; 25: 648-62.
40. Pil J, Van der Veken P, Bal G, et al. Synthesis and electrophysiological characterization of cyclic morphiceptin analogues. Biochem Pharmacol 2004; 67: 1887-95.
41. Janecka A, Fichna J, Kruszynski R, et al. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. Biochem Pharmacol 2005; 71: 188-95.
42. Tseng LF. The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse. Jpn J Pharmacol 2002; 89: 216-20.
43. Perlikowska R, doRego JC, Cravezic A, et al. Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides 2010; 31: 339-45.
44. Fichna J, Perlikowska R, Wyrebska A, et al. Effect of 2',6'- dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. Bioorg Med Chem 2011; 19: 6977-81.
45. Schiller PW, Nguyen TM-D, Lemieux C. Synthesis and opioid activity profiles of cyclic dynorphin analogs. Tetrahedron 1988; 44: 733-43.
46. Kawasaki AM, Knapp RJ, Kramer TH, et al. Design and synthesis of highly potent and selective cyclic dynorphin A analogues. J Med Chem 1990; 33: 1874-9.
47. Kawasaki AM, Knapp RJ, Kramer TH, et al. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem 1993; 36: 750-57.
48. Meyer JP, Collins N, Lung FD, et al. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11. J Med Chem 1994; 37: 3910-7.
49. Lung FD, Collins N, Stropova D, et al. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2. J Med Chem 1996; 39: 1136-41.
50. Arttamangkul S, Ishmael JE, Murray TF, et al. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the address sequence. J Med Chem 1997; 40: 1211-8.
51. Vig BS, Murray TF, Aldrich JV. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3. J Med Chem 2004; 47: 446-55.
52. Schiller PW, Berezowska I, Nguyen TM-D, et al. Novel ligands lacking a positive charge for the ä-and í-opioid receptors. J Med Chem 2000; 43: 551-9.
53. Lu Y, Weltrowska G, Lemieux C, et al. Stereospecific synthesis of (2S)-2-methyl-3-(2',6'-dimethyl-4'-hydroxyphenyl)-propionic acid (Mdp) and its incorporation into an opioid peptide. Bioorg Med Chem Lett 2001; 11: 323-5.
54. Lu Y, Nguyen TM, Weltrowska G, et al. [2',6'- Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an Nterminal amino group: potent and selective kappa opioid antagonists. J Med Chem 2001; 44: 3048-53.
55. Schiller PW, Weltrowska G, Nguyen TM, et al. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists. Life Sci 2003; 73: 691-8.
56. Vig BS, Murray TF, Aldrich JV. A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus. J Med Chem 2003; 46: 1279-82.
57. Vig BS, Murray TF, Aldrich JV. Synthesis of novel basic head-toside- chain cyclic dynorphin A analogs: strategies and side reactions. Biopolymers 2003; 71: 620-37.
58. Cardillo G, Gentilucci L, Tolomelli A, et al. Synthesis and evaluation of the affinity toward mu-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]. J Med Chem 2004; 47: 5198-203.
59. Bedini A, Baiula M, Gentilucci L, et al. Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model. Peptides 2010; 31: 2135-2140.
60. Gentilucci L, Squassabia F, Demarco R, et al. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR. FEBS J 2008; 275: 2315-37.
61. Shreder K, Zhang L, Dang T, et al. Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics. J Med Chem 1998; 41: 2631-5.
62. Baker TJ, Rew Y, Goodman M. Novel reagents and reactions for drug design. Pure Appl Chem 2000; 72: 347-54.
63. Schiller PW, Eggimann B, DiMaio J, et al. Cyclic enkephalin analogs containing a cystine bridge. Biochem Biophys Res Commun 1981; 101: 337-43.
64. Mosberg HI, Hurst R, Hruby VJ, et al.[D-Pen2, LCys5] enkephalinamide and[D-Pen2, D-Cys5] enkephalinamide, conformationally constrained cyclic enkephalinamide analogs with delta receptor specificity. Biochem Biophys Res Commun 1982; 106: 506-12.
65. Mosberg HI, Hurst R, Hruby VJ, et al. Conformationally constrained cyclic enkephalin analogs with pronounced delta opioid receptor agonist selectivity. Life Sci 1983; 32: 2565-9.
66. Mosberg HI, Hurst R, Hruby VJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci USA 1983; 80: 5871-4.
67. Gacel G, Daugé V, Breuzé P, et al. Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors. J Med Chem 1988; 31: 1891-7.
68. Shimohigashi Y, Costa T, Pfeiffer A, et al. Delta EPhe4-enkephalin analogs. Delta receptors in rat brain are different from those in mouse vas deferens. FEBS Lett 1987; 222: 71-4.
69. Akiyama K, Gee KW, Mosberg HI, et al. Characterization of [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG 108-15). Proc Natl Acad Sci USA 1985; 82: 2543-7.
70. Meraldi JP, Hruby VJ, Brewster AI. Relative conformational rigidity in oxytocin and (1-penicillamine)-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. Proc Natl Acad Sci USA 1977; 74: 1373-7.
71. Hruby V, Kao L-F, Pettitt BM, et al. The conformational properties of the delta opioid peptide [D-Pen2, D-Pen5]enkephalin in aqueous solution determined by NMR and energy minimalization calculations. J Am Chem Soc 1988; 110: 3351-9.
72. Flippen-Anderson JL, Hruby VJ, Collins N, et al. X-ray structure of [D-Pen2,D-Pen5]enkephalin, a highly potent, delta-opioid receptor- selective compound: comparisons with proposed solution conformations. J Am Chem Soc 1994; 116: 7523-31.
73. Weber SJ, Greene DL, Hruby VJ, et al. Whole body and brain distribution of [3H]cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J Pharmacol Exp Ther 1992; 263: 1308-16.
74. Greene DL, Hau VS, Abbruscato TJ, et al. Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J Pharmacol Exp Ther 1996; 277: 1366-275.
75. Fadel V, Bettendorff P, Herrmann T, et al. Automated NMR structure determination and disulfide bond identification of the myotoxin crotamine from Crotalus durissus terrificus. Toxicon 2005; 46: 759-67.
76. Toth G, Kramer TH, Knapp R, et al.[D-Pen2,D-Pen5]enkephalin analogues with increased affinity and selectivity for delta opioid receptors. J Med Chem 1990; 33: 249-53.
77. Mosberg HI, Omnaas JR, Medzihradsky F, et al. Cyclic, disulfideand dithioether-containing opioid tetrapeptides: development of a ligand with high delta opioid receptor selectivity and affinity. Life Sci 1988; 43: 1013-20.
78. Heyl DL, Mosberg HI. Modification of the Phe3 aromatic moiety in delta receptor-selective dermorphin/deltorphin-related tetrapeptides. Effects on opioid receptor binding. Int J Pept Protein Res 1992; 39: 450-7.
79. Weltrowska G, Berezowska I, Lemieux C, et al. N-methylated cyclic enkephalin analogues retain high opioid receptor binding affinity. Chem Biol Drug Des 2010; 75: 182-8.
80. Misicka A, Lipkowski AW, Horvath R, et al. Delta opioid receptor selective ligands; DPLPE-deltorphin chimeric peptide analogues. Int J Pept Protein Res 1994; 44: 80-4.
81. Terenius L. Somatostatin and ACTH are peptides with partial antagonist- like selectivity for opiate receptors. Eur J Pharmacol 1976; 38: 211-3.
82. Pelton JT, Gulya K, Hruby VJ, et al. Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity. Proc Natl Acad Sci USA 1985; 82: 236-9.
83. Pelton JT, Kazmierski W, Gulya K, et al. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem 1986; 29: 2370-5.
84. Kazmierski W, Wire WS, Lui GK, et al. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. J Med Chem 1988; 31: 2170-7.
85. Shook JE, Pelton JT, Lemcke PK, et al. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. J Pharmacol Exp Ther 1987; 242: 1-7.
86. McFadyen IJ, Sobczyk-Kojiro K, Schaefer MJ, et al. Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor. J Pharmacol Exp Ther 2000; 295: 960-6.
87. McFadyen IJ, Ho JC, Mosberg HI, et al. Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-DPen] NH2 (Et): effects on opioid receptor binding and activation. J Pept Res 2000; 55: 255-61.
88. Przydzial MJ, Pogozheva ID, Bosse KE, et al. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor. J Pept Res 2005; 65: 333-42.
89. Przydzial MJ, Pogozheva ID, Ho JC, et al. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors. J Pept Res 2005; 66: 255-62.
90. Chefer VI, Shippenberg TS. Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology 2009; 34: 887-98.
91. Shippenberg TS, Chefer VI, Thompson AC. Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry 2009; 65: 169-74.
92. Timár J, Gyarmati Z, Fürst Z. The development of tolerance to locomotor effects of morphine and the effect of various opioid receptor antagonists in rats chronically treated with morphine. Brain Res Bull 2005; 64: 417-24.
93. Purington LC, Pogozheva ID, Traynor JR, et al. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. J Med Chem 2009; 52: 7724-31.
94. Fowler CB, Pogozheva ID, LeVine H 3rd, et al. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry 2004; 43: 8700-10.
95. Fowler CB, Pogozheva ID, Lomize AL, et al. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Biochemistry 2004; 43: 15796-810.
96. Nutt RF, Veber DF, Saperstein R. Synthesis of nonreducible bicyclic analogs of somatostatin. J Am Chem Soc 1980; 102: 6539-45.
97. Stymiest JL, Mitchell BF, Wong S, et al. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett 2003; 5: 47-9.
98. Berezowska I, Chung NN, Lemieux C, et al. Cyclic dermorphin tetrapeptide analogues obtained via ring-closing metathesis. Acta Biochim Pol 2006; 53: 73-6.
99. Berezowska I, Chung NN, Lemieux C, et al. Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)- Cys]NH(2) retain high opioid activity. J Med Chem 2007; 50: 1414-7.
100. Mollica A, Guardiani G, Davis P, et al. Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly- Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem 2007; 50: 3138-42.
101. Berezowska I, Lemieux C, Chung NN, et al. Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis. Chem Biol Drug Des 2009; 74: 329-34.
102. Goodman M, Zapf C, Rew Y. New reagents, reactions, and peptidomimetics for drug design. Biopolymers 2001; 60: 229-45.
103. Rew Y, Malkmus S, Svensson C, et al. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands. J Med Chem 2002; 45: 3746-54.
104. Besse D, Lombard MC, Zajac JM, et al. Pre- and postsynaptic location of mu, delta and kappa opioid receptors in the superficial layers of the dorsal horn of the rat spinal cord. Prog Clin Biol Res 1990; 328: 183-6.
105. Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 1997; 41: 94-111.
106. Ambo A, Hamazaki N, Yamada Y, et al. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides. J Med Chem 2001; 44: 4015-1018.
107. Kitayama M, Barnes TA, Carra G, et al. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1- 14)NH2. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 528-37.
108. Pawlak D, Chung NN, Schiller PW, et al. Synthesis of a novel sidechain to side-chain cyclized enkephalin analogue containing a carbonyl bridge. J Pept Sci 1997; 3: 277-81.
109. Pawlak D, Oleszczuk M, Wójcik J, et al. Highly potent side-chain to side-chain cyclized enkephalin analogues containing a carbonyl bridge: synthesis, biology and conformation. J Pept Sci 2001; 7: 128-40.
110. Filip K, Oleszczuk M, Pawlak D, et al. Potent side-chain to sidechain cyclized dermorphin analogues containing a carbonyl bridge. J Pept Sci 2003; 9: 649-57.
111. Filip K, Oleszczuk M, Wójcik J, et al. Cyclic enkephalin and dermorphin analogues containing a carbonyl bridge. J Pept Sci 2005; 11: 347-52.
112. Kotlinska J, Bochenski M, Lagowska-Lenard M, et al. Enkephalin derivative, cyclo[Nepsilon,Nbeta-carbonyl-D-Lys2, Dap5] enkephalinamide (cUENK6), induces a highly potent antinociception in rats. Neuropeptides 2009; 43: 221-8.
113. Witkowska E, Nowakowski M, Oleszczuk M, et al. Ureido group containing cyclic dermorphin(1-7) analogues: synthesis, biology and conformation. J Pept Sci 2007; 13: 519-28.
114. Zieleniak A, Rodziewicz-Motowidö S, Rusak L, et al. Deltorphin analogs restricted via a urea bridge: structure and opioid activity. J Pept Sci 2008; 14: 830-7.
115. Kotlinska JH, Gibula-Bruzda E, Witkowska E, et al. Antinociceptive effects of two deltorphins analogs in the tail-immersion test in rats. Peptides 2013; 39: 103-10.
116. Ciszewska M, Kwasiborska M, Nowakowski M, et al. N- (ureidoethyl)amides of cyclic enkephalin analogs. J Pept Sci 2009; 15: 312-8.
117. Bańkowski K, Witkowska E, Michalak OM, et al. Synthesis, biological activity and resistance to proteolytic digestion of new cyclic dermorphin/deltorphin analogues. Eur J Med Chem 2013; 63C: 457-67.
118. Ciszewska M, Ruszczyńska K, Oleszczuk M, et al. Cyclic enkephalin-deltorphin hybrids containing a carbonyl bridge: structure and opioid activity. Acta Biochim Pol 2011; 58: 225-30.
119. Touati-Jallabe Y, Chiche L, Hamzé A, et al. Cyclic peptides with a diversely substituted guanidine bridge: solid-phase synthesis and structural analysis. Chemistry 2011; 17: 2566-70.
120. Witt K, Gillespie TJ, Huber JD, et al. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001; 22: 2329-43.
121. Schiller PW, Nguyen TM-D, Miller J. Synthesis of side-chain to side-chain cyclized peptide analogs on solid supports. Int J Peptide Protein Res 1985; 25: 171-7.
122. Felix AM, Wang CW, Heimer EP, et al. Applications of BOP reagent in solid phase synthesis II. Solid phase side-chain to sidechain cyclizations using BOP reagent. Int J Peptide Protein Res 1988; 31: 231-8.
123. Lyttle MH, Hudson D. Allyl-based side-chain protection for SPPS. In: Smith JA, Rivier JE (eds.) Peptides: chemistry, structure and biology. ESCOM Leiden; 1992. pp 583-4.
124. Chan WC, Bycroft BW, Evans DJ, et al. A novel 4-aminobenzyl ester-based carboxy-protecting group for synthesis of atypical peptides by Fmoc-But solid-phase chemistry. J Chem Soc Chem Commun 1995; 21: 2209-10.
125. Chhabra SR, Hothi B, Evans DJ, et al. An appraisal of new variants of Dde amine protecting group for solid phase peptide synthesis. Tetrahedron Lett 1998; 39: 1603-6.
126. Aletras A, Barlos K, Gatos D, et al. Preparation of the very acidsensitive Fmoc-Lys(Mtt)-OH Application in the synthesis of sidechain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs. Int J Peptide Protein Res 1995; 45: 488-96.
127. Yue C, Thierry J, Potier P. 2-phenyl isopropyl esters as carbonyl terminus protecting groups in the fast synthesis of peptide fragments. Tetrahedron Lett 1993; 34: 323-6.
128. Mansfeld FM, Toth I. Synthesis and plasma stability of disulfidebridged cyclic endomorphin-1 derivatives. Int J Org Chem 2012; 2: 1-6.